UCB

Major Shareholding Notification • Jan 2, 2025

Transparency notification Wellington

Brussels (Belgium), 02 January 2025 – 20:00 (CET) – Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02210, USA) on 30 December 2024.

Wellington Management Group LLP has notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has decreased and it has crossed the 3% threshold downwards, on 27 December 2024.

On 27 December 2024, Wellington Management Group LLP (taking into account the holdings of its affiliates) owned less than 3% of UCB shares with voting rights or equivalent financial instruments of the total number of shares issued by the company (194 505 658), versus 4.99% (9 705 989 UCB shares) in the previous notification dated 15 May 2024.

2. Content of the notification

• Reason for the notification: Acquisition or disposal of voting securities or voting rights; acquisition or disposal of financial instruments that are treated as voting securities.
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement:

Name	Address (for legal entities)
Wellington Management Group LLP	280 Congress Street, Boston, MA, 02210

• Date on which the threshold is crossed: 27 December 2024.
• Threshold crossed (in %): 3%.
• Denominator: 194 505 658.

0

• Notified details:

A) Voting rights	Previous notification	After the transaction
	# of voting rights		# of voting rights	% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Wellington Management Group LLP
Wellington Management International Ltd.
Wellington Management Company LLP
Subtotal

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument		Expiration date Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights		Settlement
TOTAL				0 0,00%
TOTAL (A & B)				# of voting rights		% of voting rights
			CALCULATE	0		0,00%

• Chain of controlled undertakings through which the holding is effectively held:

Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.
Wellington Management International Ltd is a direct controlled undertaking of Wellington Management Global Holdings, Ltd. which, in turn, is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.
The shares are registered in the names of the Accounts or nominees according to their respective holdings.

• Additional information: Wellington Management Company LLP and Wellington Management International Ltd are investment management companies and can exercise the voting rights at their discretion in the absence of specific instructions from the beneficial owners of the shares.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.

For further information, contact UCB:

Investor Relations Antje Witte T +32 2 559 94 14 antje.witte@ucb.com

Corporate Communications Laurent Schots T+32 2 559 92 64 laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news